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Abstract
Background: The aim of this study was to compare surgical treatment received by Aboriginal and non-Aboriginal
people with non-small cell lung cancer (NSCLC) in New South Wales (NSW), Australia and to examine whether
patient and disease characteristics are associated with any disparities found. An additional objective was to describe
the adjuvant treatments received by Aboriginal people diagnosed with NSCLC in NSW. Finally, we compared the
risk of death from NSCLC for Aboriginal and non-Aboriginal people.
Methods: We used logistic regression and competing risks regression to analyse population-based cancer registry
records for people diagnosed with NSCLC in NSW, 2001–2007, linked to hospital inpatient episodes and deaths.
We also analysed treatment patterns from a medical record audit for 170 Aboriginal people diagnosed with NSCLC
in NSW, 2000–2010.
Results: Of 20,154 people diagnosed with primary lung cancer, 341 (1.7 %) were Aboriginal. Larger proportions
of Aboriginal people were younger, female, living outside major cities or in areas of greater socioeconomic
disadvantage, smoking at the time of diagnosis and had comorbidities. Although Aboriginal people were, on
average, younger at diagnosis with non-metastatic NSCLC than non-Aboriginal people, only 30.8 % of Aboriginal
people received surgery, compared with 39.5 % of non-Aboriginal people. Further, Aboriginal people who were
not receiving surgery, at the time of diagnosis, were more likely to be younger, live in major cities and have no
comorbidities. The observed risk of death from NSCLC 5 years after diagnosis was higher for 266 Aboriginal people
(83.3 % 95 % CI 77.5–87.7) than for 15,491 non-Aboriginal people (77.6 % 95 % CI 76.9–78.3) and the adjusted
subhazard ratio was 1.32 (95 % CI 1.14–1.52). From the medical record audit, 29 % of Aboriginal people with NSCLC
had potentially curative treatment, 45 % had palliative radiotherapy/chemotherapy and 26 % had no active
treatment.
Conclusions: There are disparities in NSCLC surgical treatment and mortality for Aboriginal people compared
with non-Aboriginal people in NSW. It is imperative that Aboriginal people are offered active lung cancer treatment,
particularly those who are younger and without comorbidities and are therefore most likely to benefit, and are
provided with assistance to access it if required.
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Background
Lung cancer is the most common cause of cancer
death for both the Australian Aboriginal and non-
Aboriginal populations [1]. In New South Wales
(NSW) the 5-year lung cancer-specific survival for
Aboriginal people has been reported to be approxi-
mately half that of non-Aboriginal people [2]. The
reasons for this difference in survival are complex
and have not yet been explored in NSW, although a
study from Queensland [3], another state in Australia,
attributed most of the difference to disparities in the
medical treatment received by Aboriginal and non-
Aboriginal people. This study found that, after adjust-
ing for a range of disease and patient characteristics,
the probability of Aboriginal people receiving active
treatment at any stage of the illness was 35 % lower
than for non-Aboriginal people [3]. Similarly, a West-
ern Australian study [4] found that the adjusted odds
of receiving surgical treatment were 37 % lower for
Aboriginal people than non-Aboriginal people diag-
nosed with lung cancer.
Surgical resection is the most effective treatment for
non-metastatic non-small cell lung cancer (NSCLC), as
well as for highly selected cases with a single site of
metastases [5, 6]. However, the feasibility of surgery de-
pends on the extent and location of the disease, and the
ability of the patient to tolerate the procedure [7]. When
surgical resection is not indicated for NSCLC, radiother-
apy, chemotherapy and/or palliative management are
recommended [5]. The optimal mix of treatments is de-
termined by disease and patient characteristics, includ-
ing spread of disease, comorbidities and age [5]. It is
possible that differences in these factors, as well as bar-
riers to treatment access, lead to differences in the treat-
ment of, and mortality from, lung cancer for Aboriginal
and non-Aboriginal people.
To date, no studies of NSCLC treatment for Aboriginal
people have been conducted in NSW, which is the most
populous state in Australia (approximately 7 million
people) and has an estimated 29 % of the total Australian
Aboriginal population of approximately 148,000 people
[8]. Aboriginal people comprise approximately 2 % of the
NSW population and, nationally, have a median age of
21 years compared with a median age for non-Aboriginal
people of 37 years [8]. Compared with Queensland and
Western Australia, Aboriginal people in NSW are much
more likely to live in major cities and inner regional areas
[8], and therefore may have better access to specialist lung
cancer treatment centres.
We use the descriptor ‘Aboriginal people’ through-
out this paper to refer to the original people of
Australia and their descendants, as endorsed by the
Aboriginal Health and Medical Research Council in
NSW and NSW Health [9].
The aim of this study was to compare surgical treat-
ment for NSW Aboriginal and non-Aboriginal people
diagnosed with non-metastatic NSCLC, and to examine
the degree to which differences in patient and disease
characteristics are associated with any disparities found.
An additional objective was to describe radiotherapy and
chemotherapy treatment for Aboriginal people diag-
nosed with NSCLC in NSW. Finally, we compared Abo-
riginal and non-Aboriginal people’s risk of death from
NSCLC.
Methods
The methods used here have been described previously
[10–12], and, briefly, involve the analysis of two different
linked datasets. The first dataset (“NSW population
data”) contained 21,127 incident lung cancer cases for
2001–2007 from the NSW Central Cancer Registry
(CCR), linked to hospital episode records and death re-
cords. The second dataset (“Patterns of Care data”) com-
prised data from a medical records audit linked to CCR,
hospital and death records. Eligible cases were aged
18 years and over, diagnosed with primary lung cancer
(ICD-O-3 codes “C33” and “C34” and morphology codes
ending in/3), and resident in NSW at diagnosis. The
probabilistic linkage of records in the different datasets
was carried out by the Centre for Health Record Linkage
(CHeReL) using ChoiceMaker software and privacy-
preserving methods (ChoiceMaker Technologies Inc.,
New York, US). The CHeReL reports approximately




All invasive cancers diagnosed in NSW have been re-
quired by statute to be notified to the NSW Central
Cancer Registry (CCR) since 1972. All inpatient episodes
in all public and private hospitals in NSW are docu-
mented in and available from the NSW Ministry of
Health’s Admitted Patient Data Collection (APDC).
As the focus of this study was comparing treatment
after diagnosis, we excluded from the analysis 567
people (2.7 %) who were notified to the CCR by death
certificate or after autopsy only. The remaining 20,560
people were linked to the APDC for the period 1 July
2000 to 30 June 2009. Death records including Aborigi-
nal status up to 31 December 2007 were obtained from
the Australian Bureau of Statistics (ABS). After exclud-
ing people with no matching APDC record (406, 1.9 %)
as their Aboriginal status was unknown and they may
have been treated in hospitals outside NSW [13] 20,154
people were included in the analysis (Fig. 1).
In this analysis, a person was determined to be Abori-
ginal if they were listed as Aboriginal and/or Torres
Gibberd et al. BMC Cancer  (2016) 16:289 Page 2 of 11
Strait Islander in any of their matching APDC or ABS
records. We have not reported data separately for Torres
Strait Islander people as there were very few identified
in the source datasets.
Lung cancers were grouped by histological type as
NSCLC, small cell lung cancer (SCLC) and “other and
unspecified”, similar to the groupings used by the
Australian Institute of Health and Welfare [14]. NSCLC
included squamous cell carcinoma, adenocarcinoma, large
cell carcinoma and the group defined by the Australian
Institute of Health and Welfare as “other specified
carcinoma”.
Surgical treatment for localised and regional (“non-
metastatic”) NSCLC was identified from the procedure
codes listed in the APDC. Surgical treatment was
defined as pneumonectomy, lobectomy, lung resection
or resection of endotracheal tumour. Pleurodesis was
not included as the main intent of this procedure is pal-
liative. We restricted our analysis to surgical treatment
because radiotherapy and chemotherapy, largely admin-
istered in outpatient services, are not routinely recorded
in the APDC [13].
Age at diagnosis, sex, local government area (LGA) of
residence at time of diagnosis, month and year of diag-
nosis, spread of disease at diagnosis and histology were
obtained from the CCR. Spread of disease at diagnosis
was reported by the CCR in four categories: localised
(the tumour was contained within the organ in which it
originated), regional (the tumour had spread to sur-
rounding organs, adjacent tissue and/or nearby lymph
nodes), distant (metastatic disease) and unknown [15].
We could not assess differences between Aboriginal and
non-Aboriginal people in the use of Positron Emission
Tomography (PET) for cancer staging as we only had
inpatient records and PET scans can be done on an
outpatient basis.
Each person was allocated to one of three categories
of geographic remoteness using the ARIA+ (Accessibil-
ity/Remoteness Index for Australia) [16] value for their
LGA of residence. The ARIA+ index is calculated using
road distances of a LGA to the nearest population cen-
tres or ‘service centres’. The service centres are cate-
gorised into major cities, inner regional and rural (which
included outer regional, remote and very remote) based
on population size. Quintiles of socioeconomic disad-
vantage were obtained by mapping their LGA of resi-
dence to the ABS Socio-Economic Indexes for Areas
(SEIFA) Index of Relative Socio-Economic Advantage
and Disadvantage [17, 18].
Information about comorbidities was obtained from
the APDC diagnosis codes, which include the primary
reason for hospitalisation and additional comorbidities
[19]. The presence of non-cancer comorbidities included
in the Charlson Comorbidity Index [20] was obtained
from hospital admission records from 12 months prior
to diagnosis to 6 months after diagnosis. Those people
who were not admitted to a NSW hospital during this
18 month period were excluded from analyses of factors
related to receiving treatment (Fig. 1).
Smoking status was obtained from the APDC diagno-
sis codes. There is no code for non-smokers and it is not
mandatory to record smoking status in the APDC.
Fig. 1 Inclusion and exclusion criteria for the NSW population data of people with lung cancer diagnosed in NSW 2001–2007
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“Current smokers” were those who had a record of being
a current smoker after diagnosis. “Former smokers” were
those whose last smoking-related diagnosis prior to their
cancer diagnosis was former smoker. “Ever smokers”
were people with a record of current and/or former
smoking, but it was not possible to determine if they
were current smokers when they were diagnosed with
cancer. “Never smokers” were defined as those who did
not have any diagnosis of current or former smoker and
were admitted at least once to a NSW hospital that was
considered to record smoking status reliably, specifically
at least 20 % of admissions had a smoking-related rec-
ord. For the remainder, smoking status was coded as
unknown.
Patterns of Care (POC) data
The Patterns of Care data were obtained through a med-
ical records audit of a sample of Aboriginal people resi-
dent in NSW diagnosed with any invasive cancer in
2000–2011. Data were collected from 23 public hospitals
and three Clinical Cancer Registries in NSW. The hospi-
tals and registries were chosen based on size, recording
of Aboriginal status, ability to extract electronic patient
lists and the availability of a local Principal Investigator.
Field officers confirmed Aboriginal status and extracted
diagnosis and treatment information from paper and
electronic medical records. In total, data were collected
for 1304 Aboriginal people, of whom 219 were diag-
nosed with lung cancer in 2000–2010.
We collected disease and treatment information using
a form largely based on a form developed for a previous
study [21]. The data collection form used in this study
was reviewed by three oncologists to ensure that it cov-
ered all current forms of treatment. Data on disease
characteristics included topography, histology, lymph
node involvement and evidence of distant metastases.
Spread of disease was categorized into three groups:
non-metastatic, metastatic and unknown. Information
on surgery, radiotherapy and chemotherapy included the
timing of treatment, the intent of treatment (curative or
palliative), and reasons for no treatment. Stereotactic
radiotherapy became available in NSW after 2010 and so
was not part of the standard treatment for NSCLC dur-
ing the study period.
Records in the POC data were linked to the APDC for
July 2000 to June 2009, the NSW Registry of Births,
Deaths and Marriages death records for January 2000 to
June 2010, and the CCR for 2000 to 2008 by the
CHeReL. Histological type, place of residence, socioeco-
nomic disadvantage and comorbidities were assigned in
the same way as for the NSW population data. When in-
formation about treatment was missing in the POC data,
but present in the APDC, details from the APDC were
used to supplement the POC data.
Statistical analysis
Differences between Aboriginal and non-Aboriginal people
with lung cancer were tested using Pearson’s chi-squared
test. Tests of differences between Aboriginal people in the
NSW population data and the POC data were not con-
ducted, due to the overlap in the two datasets.
Logistic regression models were used to compare the
odds of having surgical treatment for non-metastatic
NSCLC for Aboriginal and non-Aboriginal people in the
NSW population data. All models included Aboriginal
status as an explanatory variable and the full model also
contained: sex, age group, spread of disease at diagnosis,
year of diagnosis, comorbidities, socioeconomic disad-
vantage quintiles and place of residence. Finally, smok-
ing status was added to this model to investigate the
additional effect on the odds of surgical treatment for
Aboriginal compared to non-Aboriginal people.
Differences in the relationship between Aboriginal sta-
tus and surgery across strata defined by the other covari-
ates were tested by adding interaction terms to the full
logistic regression model, with some strata collapsed, as
shown in Table 3 [22]. The difference in the time from
diagnosis to surgery for those who had surgery was
tested using the Mann–Whitney test.
The risk of death from NSCLC was analysed using
competing risks regression [23, 24]. Follow-up was cen-
sored at 31 December 2008 for all surviving people, with
non-lung cancer deaths treated as the competing risk.
The main factor of interest was Aboriginal status. Sex,
age group, spread of disease at diagnosis, year of diagno-
sis, surgical treatment, comorbidities, socioeconomic
disadvantage quintiles, place of residence and smoking
status were also included in the full regression model.
We obtained the sub-distribution hazard ratios (SHRs)
for each factor in the full model.
All analyses were performed using SAS software
(release 9.3; SAS Institute Inc, Cary, North Carolina),
R 3.1.0 [25] and Stata/IC 13.1 (StataCorp).
Ethical approval
The study using the NSW population data and the linkage
of the Patterns of Care data to NSW health datasets were
approved by the NSW Population and Health Services Re-
search Ethics Committee and the Human Research Ethics
Committee of the Aboriginal Health and Medical Research
Council. Data collection for the Patterns of Care study was
approved by the ethics committees of Royal Prince Alfred
Hospital and the Aboriginal Health and Medical Research
Council. Local Regional Governance Offices granted Site
Specific Approval for data collection in participating hospi-
tals and Clinical Cancer Registries. Seeking individual
patient consent was determined to be impracticable by the
lead ethics committees given the nature of the disease and
the retrospective study methods that have been used.
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Table 1 Demographic and disease characteristics of Aboriginal and non-Aboriginal people diagnosed with lung cancer in NSW
NSW population data, diagnosed 2001–2007 Patterns of Care (POC) data, diagnosed 2001–2010
Non-Aboriginal Aboriginal Aboriginal
n % n % p-valuea n %
All people 19,813 341 219
Sex
Male 12,540 63 191 56 0.006 122 56
Female 7273 37 150 44 97 44
Age at diagnosis (years) <0.001
18–49 930 5 39 11 31 14
50–59 2609 13 79 23 65 30
60–69 5292 27 110 32 71 32
70–79 7117 36 87 26 45 21
80+ 3865 20 26 8 7 3
Spread of disease (from CCR)b 0.586
Localised 4602 23 79 23 40 22
Regional 3352 17 67 20 42 23
Distant 7281 37 118 35 67 37
Unknown 4578 23 77 23 30 17
Place of residence at diagnosisb <0.001
Major cities 13,687 69 125 37 77 43
Inner regional 4637 23 122 36 60 34
Ruralc 1489 8 94 28 42 23
Comorbiditiesd
Diabetes 2735 15 67 20 0.004 46 27
Cardiovascular disease 3999 21 85 26 0.055 35 21
Chronic pulmonary disease 5381 29 132 40 <0.001 35 38
Renal disease 899 5 23 7 0.070 10 6
Any other comorbidities 2380 13 39 12 0.624 27 16
Socioeconomic disadvantage quintileb <0.001
Least disadvantaged 3031 15 22 6 12 7
Second least disadvantaged 4041 20 31 9 15 8
Third least advantaged 3375 17 44 13 36 20
Second most disadvantaged 4476 23 74 22 33 18
Most disadvantaged 4890 25 170 50 83 46
Smoking status <0.001
Current smoker 5582 28 143 42 101 46
Ever smokere 5934 30 99 29 61 28
Former smoker 4237 21 56 16 23 11
Never smoker 3623 18 35 10 22 10
Unknown 437 2 8 2 12 5
Histological type (from CCR)b 0.059
Non-small cell 16,369 83 273 80 142 79
Small cell 2533 13 57 17 34 19
Other and unspecified 911 5 11 3 3 2
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Results
NSW population data
Of the 20,154 people with lung cancer diagnosed in
NSW in 2001–2007, 341 (1.7 %) were identified as Abo-
riginal (Table 1). Compared to the non-Aboriginal
people, larger proportions of Aboriginal people were fe-
male (44 % versus 37 %) or under the age of 60 years at
diagnosis (35 % versus 18 %) (Table 1). Aboriginal people
were more likely to live outside major cities and in more
socioeconomically disadvantaged areas, and were also
more likely to be smoking around the time of diagnosis,
and have comorbid diabetes or chronic pulmonary disease.
Spread of disease at diagnosis was similar for Aboriginal
and non-Aboriginal people. SCLC was more common for
Aboriginal people, but the difference was not statistically
significant.
Surgical treatment for non-metastatic NSCLC
When we restricted the analysis to people diagnosed
with non-metastatic NSCLC, 30.8 % of the 120 Aborigi-
nal people received surgery, compared with 39.5 % of
non-Aboriginal people. The median time between diag-
nosis and surgery was similar for Aboriginal and non-
Aboriginal people with non-metastatic NSCLC (24 days
for Aboriginal and 20 days for non-Aboriginal people,
p = 0.86). The types of surgical treatment received were
similar, with 57 % of Aboriginal people and 58 % of
non-Aboriginal people having lobectomies. The age-
adjusted odds of having surgery were 46 % lower for
Aboriginal than non-Aboriginal people (OR 0.54, 95 %
CI 0.36–0.80). After also adjusting for sex, year of diag-
nosis, spread of disease, place of residence, comorbidi-
ties and socioeconomic disadvantage, the difference
was reduced (OR 0.70, 95 % CI 0.46–1.05) and no lon-
ger statistically significant (Table 2). The proportions
who were never smokers in Aboriginal and non-
Aboriginal people were 10 % and 18 % respectively
(Table 1). The addition of smoking status had little
effect on the odds ratio for surgery for Aboriginal
compared with non-Aboriginal people (OR 0.68, 95 %
CI 0.46–1.03).
Overall in NSW, women, younger people, those with
localised spread of disease, those living in major cities
and areas with less socioeconomic disadvantage, and
those without cardiovascular disease, renal disease or
other comorbidities were more likely to receive surgery
for their non-metastatic NSCLC (Table 2). The inter-
action between Aboriginal status and comorbidities was
statistically significant (p = 0.018), with Aboriginal people
with no comorbidities being approximately half as likely
to have surgery as similar non-Aboriginal people (22 %
versus 43 %), while there was no difference in propor-
tions for those with at least one comorbidity (35 %
versus 36 %) (Table 3). While this was the only statistically
significant interaction, the proportions of Aboriginal
people having surgery were consistently similar or lower
compared to non-Aboriginal people across all categories
of all covariates. For example, 51 % of non-Aboriginal
people under the age of 60 years had surgery, compared
to 37 % of older non-Aboriginal people. By contrast, for
Aboriginal people the proportions having surgery were
similar in both age groups (33 % for those under the age
of 60 years and 30 % for older people).
Risk of death from NSCLC
The observed risk of death from NSCLC 5 years after
diagnosis was higher for 266 Aboriginal people (83.3 %
95 % CI 77.5–87.7) than for 15,491 non-Aboriginal
people (77.6 % 95 % CI 76.9–78.3) (Fig. 2). After adjust-
ing for differences in sex, age at diagnosis, year of
diagnosis, spread of disease, place of residence, comor-
bidities, socioeconomic disadvantage, smoking status
and surgical treatment, Aboriginal people with NSCLC
had a greater risk of death 5 years after diagnosis com-
pared to non-Aboriginal people (Adjusted SHR 1.32
95 % CI 1.14–1.52). Sex, age at diagnosis, year of diag-
nosis, spread of disease at diagnosis, having surgical
treatment, chronic pulmonary disease, other comorbid
conditions, and socioeconomic disadvantage were also
significantly associated with the increased risk of death
from NSCLC for NSW people (Table 4).
Table 1 Demographic and disease characteristics of Aboriginal and non-Aboriginal people diagnosed with lung cancer in NSW
(Continued)
Method of diagnosis (from CCR)b 0.58
Histopathology 14,205 72 251 74 139 78
Cytology 2832 14 42 12 17 10
Clinical/Imaging/Biochemical 2776 14 48 14 23 13
CCR Central Cancer Registry
ap-values are from Pearson's χ2 test comparing frequencies in Aboriginal and non-Aboriginal people in the NSW population data only
bFor the POC data, only 179 people who linked to the CCR were included
cRural includes outer regional, remote and very remote
dPeople who were not admitted to a NSW hospital from 12 months prior to 6 months after diagnosis were excluded as information on comorbidities was not
available. In the NSW population data, 331 Aboriginal and 18,761 non-Aboriginal people were included. In the POC data, 170 Aboriginal people were included
eCurrent or former smoking status at the time of diagnosis could not be determined
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Patterns of care data
Medical records for a sample of 219 Aboriginal people
with lung cancer were reviewed. Records were extracted
after death for 172 people. For the remaining 47 people,
follow up was between 5 and 81 months, with a median
follow up of 17 months. Of the 219 people in the sam-
ple, 174 had NSCLC, although four of these had incom-
plete treatment information.
While we could not make formal statistical compari-
sons, the characteristics of the Aboriginal people in the
POC data were similar to those in the NSW population
data, except that those in the POC data were slightly
younger, less likely to have unknown spread of disease at
diagnosis and were slightly more likely to live in a major
city than the Aboriginal people in the NSW population
data (Table 1).
Treatment received for NSCLC
Potentially curative treatment was received by half (47/
94) of people with non-metastatic NSCLC and for 34/47
(72 %) of these the primary treatment was surgery. By
contrast, only 2/71 (3 %) people with metastatic NSCLC
received potentially curative treatment, while 51/71
(72 %) received palliative radiotherapy/chemotherapy. Of
the 21 people with non-metastatic NSCLC who did not
have treatment, eight died within 30 days of diagnosis.
Of the remaining 13, the reasons for not being treated
were: had comorbidities or they were considered too old
Table 2 Odds ratios for surgical treatmenta for people with
non-metastatic non-small cell lung cancer in NSW 2001–2007b
Odds ratioc (95 % CI) p-value










Spread of disease <0.001
Localised 1.00
Regional 0.81 (0.73–0.90)
Year of diagnosis 1.04 (1.02–1.07) 0.001
Place of residence at diagnosis <0.001
Major cities 1.00
Inner regional 0.69 (0.60–0.80)
Rurald 0.66 (0.51–0.83)
Comorbiditiese
Chronic pulmonary disease 1.04 (0.93–1.16) 0.526
Diabetes 1.08 (0.93–1.25) 0.300
Cardiovascular disease 0.71 (0.62–0.82) <0.001
Renal disease 0.74 (0.56–0.97) 0.029
Other comorbidities 0.60 (0.49–0.72) <0.001
Socioeconomic disadvantage quintile <0.001
Least disadvantaged 1.00
Second least disadvantaged 0.86 (0.73–1.02)
Third least disadvantaged 0.73 (0.61–0.87)
Second most disadvantaged 0.85 (0.72–1.01)
Most disadvantaged 0.63 (0.51–0.76)
CI confidence interval
aSurgical treatment includes pneumonectomy, lobectomy, lung resection or
resection of endotracheal tumour
bThere were 120 Aboriginal and 6757 non-Aboriginal people in this analysis
cOdds ratio adjusted for all other variables in the table
dRural includes outer regional, remote and very remote
ePresence vs absence of each comorbidity
Table 3 Surgical treatment within one year following diagnosis







All people 37/120 (30) 2666/6757 (39) -
Sex 0.972
Male 21/72 (29) 1637/4335 (38)
Female 16/48 (33) 1029/2422 (42)
Age at diagnosis (years) 0.367
18–59 13/40 (33) 613/1210 (51)
60+ 24/80 (30) 2053/5547 (37)
Spread of disease 0.831
Localised 20/64 (31) 1584/3928 (40)
Regional 17/56 (30) 1082/2829 (38)
Place of residence 0.641
Major cities 13/39 (33) 2044/4760 (43)
Inner regional 13/44 (30) 480/1498 (32)
Ruralc 11/37 (30) 142/499 (28)
Comorbiditiesd 0.018
No comorbidities 9/41 (22) 1390/3196 (43)
At least one comorbidity 28/79 (35) 1276/3561 (36)
Socioeconomic disadvantage 0.245
Least and second least
disadvantaged
5/15 (33) 1095/2477 (44)
Third least disadvantaged 3/16 (19) 464/1168 (40)
Second most and most
disadvantaged
29/89 (33) 1107/3112 (36)
aThere were 120 Aboriginal and 6757 non-Aboriginal people in this analysis
bFor interaction term in logistic regression containing all variables shown in
this table
cRural includes outer regional, remote and very remote
dNon-cancer comorbidities included in the Charlson Comorbidity Index
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to gain any benefit (6); patient choice (2); the tumour




For Aboriginal people in NSW with non-metastatic
NSCLC, the adjusted odds of having surgical treatment
were 30 % lower compared with non-Aboriginal people.
This finding was broadly similar to the findings from a
Queensland study, where the probability of surgery for
Aboriginal people compared to non-Aboriginal people,
matched on age, sex and place of residence, was 61 %
lower [3] and in Western Australia (where the odds were
37 % lower) [4]. However these studies included all cases
of lung cancer, not just non-small cell lung cancer. NSW
Aboriginal people also had a higher risk of death from
their non-metastatic NSCLC compared with non-
Aboriginal people after adjusting for differences in sex,
age at diagnosis, year of diagnosis, spread of disease,
place of residence, comorbidities, socioeconomic disad-
vantage, smoking status and surgical treatment.
In NSW, non-Aboriginal people with non-metastatic
NSCLC who were younger at diagnosis, without comor-
bidities or living in major cities were more likely to have
surgical treatment. However, this was not true for Abori-
ginal people. Younger Aboriginal people had only
slightly higher rates of surgery than older Aboriginal
people, and Aboriginal people living in major cities had
similar rates of surgery as those living in inner regional
and rural areas, despite their geographical proximity to
major hospitals and specialists. Counter-intuitively, Abo-
riginal people with comorbidities had a higher rate of
surgery than those without comorbidities. The opposite
was true for non-Aboriginal people. This last result is
similar to that found in the Northern Territory [26],
where the authors suggested that this may be due to
lung cancer being incidentally detected in people under
medical surveillance for other lung conditions. However,
given the small number of Aboriginal people in our
study with non-metastatic NSCLC, and the lack of infor-
mation on long term comorbidities, no firm conclusions
can be drawn. Most healthcare in Australia is paid for by
Medicare, a government run universal health care sys-
tem, through supply of care without charge in public
hospitals and subsidised medical services and pharma-
ceuticals. Some services may require a co-payment when
the fee charged is in excess of the subsidy and additional
costs such as transport to services, parking and accom-
modation (except in hospital) are not reimbursed by
Medicare. In addition, many private hospitals provide
the infrastructure needed for cancer care and private
health insurance is available to cover at least a part of
the cost of private hospital care. By arrangement in some
regional areas private cancer services provide care for
public patients free of charge when no public services
are available. Specialised cancer services in NSW are
largely located in major cities or inner regional areas.
Fig. 2 Cumulative risk of death from non-small cell lung cancer for Aboriginal and non-Aboriginal people in NSW, 2001–2007 (n = 15,757)
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Therefore the lower proportion with private health in-
surance amongst Aboriginal people [27] may have also
contributed to the lower surgical treatment rate, as it
has been previously reported [28] that NSW residents
with private health insurance (or with coverage by the
Department of Veterans’ Affairs) with localised NSCLC
had twice the odds of receiving a resection compared to
people who were uninsured.
The observed increased risk of death from NSCLC for
Aboriginal people compared to non-Aboriginal people is
similar to the patterns we have previously reported for
women with breast cancer [10] and for men with pros-
tate cancer in NSW [11], and also similar to results
others have reported for lung cancer in Queensland [3]
and the Northern Territory [26] and NSW [2]. Similar
increased risks have been shown for Maoris in New
Zealand [29], and Canadian First Nations [30] and Inuit
[31] peoples.
A limitation of the NSW population data is potential
misclassification of Aboriginal and non-Aboriginal
people in the APDC. However, an audit in 2007–08
found that all 2661 non-Aboriginal patients interviewed
were correctly classified as non-Aboriginal in the APDC
[32], suggesting that such misclassification is rare. In the
same audit, 93 % of people who identified as Aboriginal
at interview were recorded as Aboriginal in the APDC
[32]. The proportion of Aboriginal people misclassified
in our study is likely to be even lower, as we used any
recording of Aboriginal status in any linked records to
assign a person’s Aboriginal status. If the Aboriginal
people who were misclassified received more (or less)
treatment than the Aboriginal people who were correctly
classified, our results could be biased away from (or to)
the null hypothesis of similar patterns of care.
Major strengths of this study are that it was
population-based and the first study of treatment of
lung cancer for Aboriginal people in NSW. NSW has
the largest Aboriginal population and, compared with
Queensland and Western Australia, where the two
previous studies were conducted, a greater proportion
of NSW Aboriginal people lived in areas close to the
major hospitals where lung cancer treatment is pre-
dominantly provided.
Patterns of care data
One half of Aboriginal people with non-metastatic
NSCLC in the Patterns of Care data received potentially
curative treatment in the first 12 months after diagnosis,
28 % had palliative radiotherapy and/or chemotherapy
only, and 22 % had no treatment.
Limitations of the Patterns of Care data include the
non-random sampling of hospitals from which medical
records were extracted, and the exclusion of people who
did not attend a hospital following their lung cancer
Table 4 Competing risks regression model for risk of death
from non-small cell lung cancer NSW 2001–2007a
Variable name Subhazard ratiob (95 % CI) p-value









> =80 1.89 (1.71–2.09)





Year of diagnosis 0.97 (0.96–0.98) <0.001
Surgical treatmentc <0.001
Did not have surgical treatment 1.00
Had surgical treatment 0.27 (0.25–0.28)
Place of residence at diagnosis 0.889
Major cities 1.00
Inner regional 0.99 (0.94–1.05)
Rurald 1.01 (0.93–1.10)
Comorbiditiese
Diabetes 1.00 (0.94–1.06) 0.976
Cardiovascular disease 0.98 (0.93–1.04) 0.575
Chronic pulmonary disease 1.18 (1.12–1.23) <0.001
Renal disease 0.94 (0.84–1.05) 0.280
Other comorbidities 1.14 (1.07–1.22) <0.001
Socioeconomic disadvantage quintile <0.001
Least disadvantaged 1.00
Second least disadvantaged 1.04 (0.98–1.11)
Third least disadvantaged 1.17 (1.09–1.25)
Second most disadvantaged 1.11 (1.04–1.19)
Most disadvantaged 1.12 (1.04–1.20)
Smoking status 0.149
Never smoker 1.00
Current smoker 1.03 (0.98–1.08)
Ever smoker 1.06 (1.00–1.12)
Ex smoker 0.99 (0.93–1.05)
Unknown 1.01 (0.87–1.17)
CI confidence interval
aThere were 266 Aboriginal and 15,491 non-Aboriginal people in this analysis
bSubhazard ratio adjusted for all other variables in the table
cSurgical treatment included pneumonectomy, lobectomy, lung resection or
resection of endotracheal tumour
dRural includes outer regional, remote and very remote
ePresence vs absence of each comorbidity
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diagnosis. As a result, the participants may not be repre-
sentative of all Aboriginal people with lung cancer diag-
nosed in 2000–2010. However, the demographic and
disease characteristics of the Aboriginal people in the
POC data and the NSW population data were broadly
similar, suggesting that the cases in the POC data may
indeed be a good representation of Aboriginal people
with lung cancer in NSW. Also, because only people
who attended hospital after a lung cancer diagnosis were
included in the POC data, the proportions who received
treatment may be overestimated. However, this bias may
be relatively small as the proportion of Aboriginal people
with non-metastatic NSCLC receiving surgery was simi-
lar in the NSW population data and the POC data (31 %
and 36 %).
Cultural, logistical and socio-economic barriers might
explain some of this lack of optimal care. For example
limited access to transport or childcare may restrict the
ability to undergo treatment [33]. Aboriginal people in
NSW have been shown to have a lower health literacy in
relation to cancer [34] and can perceive a lack of social
inclusion [35] with healthcare systems and these may be
barriers to them receiving optimal care. Thompson et al.
[33] proposed a number of recommendations to increase
the access to new cancer services for Aboriginal people
including considering public transport and parking facil-
ities, allowing room for families to visit and/or attend
appointments and providing childcare facilities. The
same authors [36], as well as Davidson et al. [37] in a
review, also suggested that addressing cultural needs and
beliefs as well as reducing upfront medical, transport
and parking costs for Aboriginal people is likely to
improve their access to existing cancer services.
Conclusions
There is a disparity in the surgical treatment of NSCLC
between Aboriginal and non-Aboriginal people in NSW.
Counter-intuitively this is particularly true for Aboriginal
people who were younger, lived in major cities and inner
regional areas, or those without comorbidities. However,
a reasonable proportion of Aboriginal people received
radiotherapy and chemotherapy. It is therefore possible
that the disparity in surgical treatment received, particu-
larly for those diagnosed before 60 years of age, those
without comorbidities, or those living in urban areas, is
the major contributor to the increased risk of death from
lung cancer for Aboriginal people. Consequently it is im-
perative that Aboriginal lung cancer patients who are
most likely to benefit from active treatment are offered
such treatment, and are provided with assistance to ac-
cess it if required.
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Spread of disease N Number (%) Number (%) Number (%) Number (%)
Non-metastatic 94 34 (36) 13 (14) 26 (28) 21 (22)
Metastatic 71 1 (1) 1 (1) 51 (72) 18 (25)
Unknown spread 5 - - - 5 (100)
Total 170 35 (21) 14 (8) 77 (45) 44 (26)
aSurgical treatment included pneumonectomy, lobectomy, lung resection or resection of endotracheal tumour
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